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Previous experiments have shown that acidosis en-
hances isoproterenol-induced phospholamban (PHL)
phosphorylation (Mundiña-Weilenmann, C., Vittone, L.,
Cingolani, H. E., Orchard, C. H. (1996) Am. J. Physiol.
270, C107–C114). In the present experiments, performed
in isolated Langendorff perfused rat hearts, phosphoryl-
ation site-specific antibodies to PHL combined with the
quantitative measurement of 32P incorporation into
PHL were used as experimental tools to gain further
insight into the mechanism involved in this effect. At all
isoproterenol concentrations tested (3–300 nM), phos-
phorylation of Thr17 of PHL was significantly higher at
pHo 6.80 than at pHo 7.40, without significant changes in
Ser16 phosphorylation. This increase in Thr17 phospho-
rylation was associated with an enhancement of the iso-
proterenol-induced relaxant effect. In the absence of
isoproterenol, the increase in [Ca]o at pHo 6.80 (but not
at pHo 7.40) evoked an increase in PHL phosphorylation
that was exclusively due to an increase in Thr17 phos-
phorylation and that was also associated with a signifi-
cant relaxant effect. This effect and the phosphorylation
of Thr17 evoked by acidosis were both offset by the Ca21/
calmodulin-dependent protein kinase II inhibitor KN-
62. In the presence of isoproterenol, either the increase
in [Ca]o or the addition of a 1 mM concentration of the
phosphatase inhibitor okadaic acid was able to mimic
the increase in isoproterenol-induced Thr17 phosphoryl-
ation produced by acidosis. In contrast, these two inter-
ventions have opposite effects on phosphorylation of
Ser16. Whereas the increase in [Ca]o significantly de-
creased phosphorylation of Ser16, the addition of oka-
daic acid significantly increased the phosphorylation of
this residue. The results are consistent with the hypoth-
esis that the increase in phospholamban phosphoryla-
tion produced by acidosis in the presence of isoproter-
enol is the consequence of two different mechanisms
triggered by acidosis: an increase in [Ca21]i and an in-
hibition of phosphatases.
The sarcoplasmic reticulum (SR)1 Ca21-ATPase plays a piv-
otal role in the contraction and relaxation process of myocardial
cells (1). Ca21-ATPase activity is tonically inhibited by the
interaction with another SR protein named phospholamban. In
vitro experiments indicate that phosphorylation of phospho-
lamban occurs by either cAMP-dependent protein kinase (PKA)
at Ser16 or Ca21/calmodulin-dependent protein kinase II
(CaMKII) at Thr17 (2). Phosphorylation of phospholamban
causes dissociation of this protein from the pump, thus increas-
ing ATPase activity and the rate of Ca21 uptake by the SR (3).
In the intact beating heart, b-adrenoreceptor stimulation phos-
phorylates phospholamban at both Ser16 and Thr17 (4, 5). Ex-
perimental evidence from our own laboratory strongly sug-
gested that this dual phosphorylation requires both
stimulation of the PKA and CaMKII cascades of phospholam-
ban phosphorylation and simultaneous inhibition of phospho-
lamban phosphatase (5). These two prerequisites appear to be
fulfilled by b-adrenoreceptor stimulation, which, as a result of
PKA activation, triggers the activation of CaMKII by increas-
ing intracellular Ca21 and produces the inhibition of PP1, the
major phosphatase that dephosphorylates phospholamban (6–
11). This may be the reason why several attempts to phospho-
rylate phospholamban by increasing [Ca21]i through cAMP-
independent mechanisms have failed (12–15). Inhibition of
phospholamban phosphatase was required (5).
The effect of b-adrenoreceptor stimulation on phospholam-
ban phosphorylation and myocardial relaxation is dependent
on the acid-base status of the myocardium. It has been shown
that acidosis enhances isoproterenol-induced phospholamban
phosphorylation and myocardial relaxation (16). The mecha-
nism of this action remains unknown. Among several different
effects, acidosis increases intracellular calcium levels (17, 18)
and inhibits PP1 activity (16) in the rat myocardium. Thus, it
seems reasonable to consider that the acidosis enhancement of
the isoproterenol-induced increase in phospholamban phospho-
rylation could be due to a further increase either in Ser16
phosphorylation (by inhibition of PP1) and/or in Thr17 phos-
phorylation (by inhibition of PP1 and/or activation of CaMKII).
In this work, immunodetection of site-specific phosphoryl-
ated phospholamban was used in combination with the classi-
cal isotopic labeling technique of quantification of phospholam-
ban phosphorylation to investigate the contribution of each
phosphorylation site of phospholamban to the increase in the
isoproterenol-induced phosphorylation of this protein evoked
by acidosis. The possible mechanisms involved in this effect
were also explored. Simultaneous measurements of mechanical
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parameters will provide a clue to the functional consequences
of the effects observed.
EXPERIMENTAL PROCEDURES
Heart Perfusions—Experiments were performed in isolated hearts
from male Wistar rats (250–350 g of body weight) perfused according to
the Langendorff technique as described previously (13). The composi-
tion of the physiological salt solution (PSS) was 128.3 mM NaCl, 4.7 mM
KCl, 1.35 mM CaCl2, 20.2 mM NaHCO3, 0.4 mM NaH2PO4, 1.1 mM
MgCl2, 11.1 mM glucose, and 0.04 mM Na2EDTA; this solution was
equilibrated with 95% O2 and 5% CO2 to give an extracellular pH (pHo)
of 7.40 6 0.01 or with 80% O2 and 20% CO2 (pHo 6.80 6 0.02) in the
experiments of hypercapnic acidosis. The mechanical activity of the
heart was assessed by passing into the left ventricle a latex balloon
connected to a pressure transducer (Namic, Perceptor DT disposable
transducer). The balloon was filled with aqueous solution to achieve a
left ventricular end diastolic pressure of 8–14 mm Hg. Isovolumic
pressure and its first derivative were recorded on a four-channel pen
recorder (Gould Model RS 3400) fitted with a transducer amplifier
(Gould Model 13-4615-50) and a differentiating amplifier (Gould Model
13-4615-71). Hearts were perfused with PSS at pHo 7.40 for 10–15 min
for stabilization and then for the next 3 min with either PSS (control) or
different interventions as described under “Results.” To quantify 32P
incorporation into phospholamban, hearts were perfused for 60 min by
recirculation with PSS containing 10 mCi/ml 32Pi after the stabilization
period and previously to the interventions assessed. At the end of the
experimental period, the ventricles were freeze-clamped, pulverized,
and stored at 270 °C until biochemical assay.
Preparation of SR Membrane Vesicles—Membrane vesicles were pre-
pared as described previously (13), except that the pulverized tissue
from each heart was homogenized in 6 volumes of a medium containing
30 mM KH2PO4 (pH 7.0 at 4 °C), 5 mM Na2EDTA, 25 mM NaF, 300 mM
sucrose, 1 mM phenylmethylsulfonyl fluoride, and 1 mM benzamidine.
Samples from 32P-perfused hearts were homogenized in the same me-
FIG. 1. A, overall results of 32P incorporation into PHL. Experiments were performed in SR membrane vesicles isolated from rat hearts perfused
with 32P and then without and with 30 nM isoproterenol (Iso) at pHo 7.40 or 6.80 (Acidosis). Samples (300 mg) were subjected to SDS-polyacrylamide
gel electrophoresis and autoradiography. The number of experiments in each treatment group is indicated in parentheses. The results show that
acidosis enhanced isoproterenol-induced PHL phosphorylation. B, immunoblots of SR membrane vesicles isolated from hearts perfused under the
same conditions described for A. 10 mg of SR protein were resolved by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene
difluoride membranes. Blots were probed with anti-Ser16 PHL phosphopeptide (PSer16-PHL) and anti-Thr17 PHL phosphopeptide (PThr17-PHL).
Antibody binding was visualized using a chemiluminescence detection kit. PHLH and PHLL designate the pentameric and monomeric forms of
PHL, respectively.
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dium, except that the phosphate was replaced by 20 mM Tris-HCl (pH
7.0) at 4 °C. Protein was measured by the method of Bradford (19) using
bovine serum albumin as a standard. The yield was 1–2 mg of mem-
brane vesicle protein/g of cardiac tissue.
Electrophoresis and Western Blot Analysis—SDS-polyacrylamide gel
electrophoresis was performed using 10% acrylamide slab gels accord-
ing to Porzio and Pearson (20) as described previously (13). Samples for
electrophoresis were not boiled unless stated. For immunological detec-
tion of phospholamban phosphorylation sites, 10 mg of membrane pro-
tein were electrophoresed per gel lane. Proteins were transferred to
polyvinylidene difluoride membranes (Immobilon-P, Millipore Corp.)
and probed as described previously (5) according to Drago and Colyer
(21) with monoclonal antibody to phospholamban (1:5000) or polyclonal
antibodies raised against a phospholamban peptide (residues 9–19)
phosphorylated at Ser16 (1:5000) or at Thr17 (1:5000) (PhosphoProtein
Research, Leeds, United Kingdom). Immunoreactivity was visualized
by peroxidase-conjugated antibodies using a peroxidase-based chemilu-
minescence detection kit (Boehringer, Mannheim, Germany). The sig-
nal intensity of the bands on the film was quantified by optical densi-
tometric analysis. To assess 32P incorporation into phospholamban, 300
mg of membrane protein were electrophoresed per gel lane. Gels were
run in duplicate to use one of them for autoradiography and the other
for liquid scintillation counting. Quantitative results are expressed as
picomoles of 32P incorporated into phospholamban/mg of SR protein
based on the specific activity of 32P in phosphocreatine (22).
Statistics—All data are expressed as the mean 6 S.E. of n prepara-
tions. Student’s t test for unpaired observations was used to test for
statistical differences. p , 0.05 was considered statistically significant.
RESULTS
Effects of Acidosis on Phosphorylation of Phospholamban
Ser16 and Thr17 in the Absence and Presence of b-Adrenorecep-
tor Stimulation—Fig. 1A shows the overall results of 32P incor-
poration into phospholamban obtained from SR membrane ves-
icles isolated from hearts perfused with 32P and then in the
absence and presence of 30 nM isoproterenol at pHo 7.40 and
6.80. In agreement with previous findings (16), acidosis did not
increase basal phospholamban phosphorylation, but signifi-
cantly enhanced isoproterenol-induced phospholamban phos-
phorylation. Fig. 1B shows immunoblots of SR membrane ves-
icles obtained from hearts perfused under the same conditions
of Fig. 1A. Immunodetection of phosphorylation sites of phos-
pholamban indicated that the acidosis-induced increase in
phospholamban phosphorylation was exclusively due to an in-
crease in phosphorylation of Thr17. Similar results were ob-
tained when two other different isoproterenol concentrations
were explored as shown in Fig. 2. At all isoproterenol concen-
trations, acidosis significantly increased phosphorylation of
Thr17 of phospholamban without affecting phosphorylation of
Ser16. In the absence of isoproterenol, acidosis induced a slight
and nonsignificant increase in Thr17 phosphorylation and did
not modify Ser16 phosphorylation. Table I shows the mechani-
cal parameters of this experimental series. Acidosis induced a
decrease in the maximal rate of contraction (1Ṗ) in both the
absence and presence of isoproterenol. Moreover, acidosis pro-
duced an enhancement of the isoproterenol-induced relaxant
effect (decrease in t1⁄2), which attained significant levels at 30
nM isoproterenol. This relaxant effect of acidosis may be due at
least in part to the significant increase in the phosphorylation
of Thr17 produced by acidosis (see below). In the absence of
isoproterenol, the decrease in t1⁄2 produced by acidosis was not
associated with any significant increase in phosphorylation of
phospholamban and should therefore be attributed to mecha-
nisms unrelated to the phosphorylation of this protein, such as
FIG. 2. Dose-response curves of iso-
proterenol for phosphorylation of
Ser16 and Thr17 at pHo 7.40 and 6.80.
Values are the means 6 S.E. obtained
after densitometric analysis of the signal
of four (anti-Ser16 PHL phosphopeptide
(PSer16-PHL)) and five (anti-Thr17 PHL
phosphopeptide (PThr17-PHL)) immuno-
blots. Results are expressed as a percent-
age of the maximal isoproterenol (Iso; pHo
7.40)-induced site-specific phosphoryla-
tion. At all isoproterenol concentrations,
acidosis enhanced the phosphorylation of
Thr17 without affecting the phosphoryla-
tion of Ser16.
TABLE I
Effects of different interventions on mechanical
parameters in the intact heart
Rat hearts were perfused with the indicated interventions and then
freeze-clamped and processed as described under “Experimental Proce-
dures.” Results are the means 6 S.E. of n hearts. D indicates differences
with respect to the control.
Treatment n Maximal rate ofcontraction (1Ṗ)
Half-relaxation time
(t1/2)
% of control Dms
PSS
1.35 mM [Ca]o 20 99.18 6 3.05 20.2 6 0.73
1.35 mM [Ca]o-H
1 8 27.49 6 4.61a 213.75 6 3.29a
Isoproterenol
3 nM
1.35 mM [Ca]o 9 137.05 6 8.13
a 212.33 6 0.99a
1.35 mM [Ca]o-H
1 4 72.51 6 17.81a,b 218.00 6 4.02a
1.35 mM [Ca]o-OA
c 5 200.63 6 18.90a,b 220.6 6 2.16a,b
30 nM
1.35 mM [Ca]o 15 167.43 6 4.25
a 216.33 6 1.67a
1.35 mM [Ca]o-H
1 8 103.5 6 14.9b 226.13 6 2.77a,b
1.35 mM [Ca]o-OA 6 197.27 6 20.8
a 219.33 6 2.99a
3.85 mM [Ca]o 10 194.45 6 13.24
a 215.7 6 1.27a
300 nM
1.35 mM [Ca]o 5 155.11 6 6.29
a 217.00 6 2.23a
1.35 mM [Ca]o-H
1 3 119.4 6 10.55b 223.67 6 3.18a
Calcium
3.85 mM [Ca]o 13 132.74 6 10.14
a 20.54 6 0.93
3.85 mM [Ca]o-H
1 9 70.13 6 5.44a,b 29.55 6 2.27a,b
a p , 0.05 when compared with the control.
b p , 0.05 with respect to the same situation in the absence of either
acidosis or okadaic acid. The mechanical data correspond to the bio-
chemical data of hearts used in the immunodetection experiments.
c OA, okadaic acid.
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a decrease in the calcium sensitivity of the myofilaments as
suggested by previous results (16).
Does the Increase in [Ca]o Mimic the Acidosis Enhancement
of Isoproterenol-induced Thr17 Phosphorylation?—Fig. 3A
shows immunoblots of SR membrane vesicles obtained from
hearts perfused in the absence and presence of isoproterenol at
[Ca]o 5 1.35 mM and in the presence of isoproterenol at [Ca]o 5
3.85 mM. Fig. 3B shows the overall results of 10 different
experiments of this type. Increasing [Ca]o in the presence of
isoproterenol significantly increased phosphorylation of Thr17.
Unexpectedly, phosphorylation of Ser16 was significantly de-
creased. The opposite effects of increasing [Ca]o in the presence
of isoproterenol on phosphorylation of phospholamban residues
may explain the small effect of this maneuver on total phos-
pholamban phosphorylation. As shown in Fig. 4, increasing
[Ca]o from 1.35 to 3.85 mM evoked a small and nonsignificant
increase in the phosphorylation of phospholamban induced by
isoproterenol. Table I depicts the mechanical results of this
experimental series. The increase in calcium supply to the cell
in the presence of 30 nM isoproterenol did not modify the
isoproterenol-induced increase in either contractility or relax-
ation. This result is consistent with the lack of effect of increas-
ing [Ca]o in the presence of isoproterenol on total phospholam-
ban phosphorylation as quantified by 32P incorporation into
phospholamban (Fig. 4).
The decrease in Ser16 phosphorylation produced by increas-
ing [Ca]o in the presence of isoproterenol did not occur during
acidosis. This result suggests that other mechanisms triggered
by the acidosis may be playing a role. One of these putative
mechanisms is the acidosis-induced inhibition of phosphatases,
which might be offsetting the effect of an increase in [Ca21]i
on Ser16 phosphorylation. In the next two sections, we will
therefore explore the possible role of phosphatases in the
acidosis enhancement of isoproterenol-induced phospholamban
phosphorylation.
Does the Inhibition of Phosphatases Mimic the Acidosis En-
hancement of Isoproterenol-induced Thr17 Phosphorylation?—
Fig. 5A shows immunoblots of SR membrane vesicles obtained
from hearts perfused at two different isoproterenol concentra-
tions, 3 and 30 nM (pHo 7.40), in the absence and presence of 1
FIG. 3. A, immunoblots of SR membrane vesicles isolated from hearts perfused without and with 30 nM isoproterenol (iso) at [Ca]o 5 1.35 or 3.85
mM. All experiments were done at pHo 7.40. 10 mg of SR protein were resolved by SDS-polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride membranes. Blots were probed as described for Fig. 1B. B, means 6 S.E. obtained after densitometric analysis of the
signal of 8–10 immunoblots. Results are expressed as a percentage of isoproterenol ([Ca]o 5 1.35 mM)-induced site-specific phosphorylation.
Increasing [Ca]o significantly enhanced isoproterenol-induced Thr
17 phosphorylation. In contrast, increasing [Ca]o produced a significant decrease
in isoproterenol-induced Ser16 phosphorylation. PSer16-PHL and PThr17-PHL, anti-Ser16 and anti-Thr17 PHL phosphopeptides, respectively; PHLH
and PHLL, pentameric and monomeric forms of PHL, respectively.
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mM okadaic acid, a PP1 inhibitor. To compare the effects of
okadaic acid with those of acidosis, SR membranes obtained
from hearts perfused at 3 and 30 nM isoproterenol at pHo 6.80
were run in parallel. As already shown in Fig. 2, acidosis
enhanced only isoproterenol-induced Thr17 phosphorylation
without affecting Ser16 phosphorylation. In contrast, okadaic
acid enhanced the isoproterenol-induced phosphorylation of
both Ser16 and Thr17 at the two isoproterenol concentrations.
Fig. 5B shows the mean values obtained by optic densitometric
analysis of the different experiments of this series. These find-
ings revealed that the sole inhibition of phosphatases by oka-
daic acid has a different effect on phosphorylation of Ser16 than
that produced by acidosis. They also showed that even at the
higher isoproterenol concentration used, which produced the
maximum phosphorylation of phospholamban at pHo 7.40 (5),
phosphatases are not maximally inhibited. Evidence for an
enhancement of the isoproterenol-induced increase in phospho-
lamban phosphorylation produced by okadaic acid has been
previously reported in isolated myocytes (10). The present re-
sults further showed that this increase in phospholamban
phosphorylation is due to the simultaneous increase in the
phosphorylation of both Thr17 and Ser16 of phospholamban.
Table I shows the effects of okadaic acid in the presence of
isoproterenol on the mechanical parameters of contraction and
relaxation. At both isoproterenol concentrations, okadaic acid
produced a further decrease in the isoproterenol-induced de-
crease of t1⁄2. This reduction attained significant levels at 3 nM
isoproterenol. Okadaic acid also significantly increased the pos-
itive inotropic effect of this isoproterenol concentration without
affecting the effect of 30 nM isoproterenol on contractility.
Does Acidosis Increase Phospholamban Phosphorylation in
the Absence of Isoproterenol?—The rationale behind this group
of experiments was to study the effects of stimulating the
CaMKII pathway of phospholamban phosphorylation in the
absence of the inhibition of phosphatases produced by cAMP-
dependent mechanisms (7–11). Previous experiments have
shown that in the absence of isoproterenol, the increase in [Ca]o
did not phosphorylate phospholamban unless the phosphatases
were inhibited. This was so even when the increase in contrac-
tility (and therefore cytosolic calcium) was similar to that
evoked by isoproterenol or more prolonged as during tetani (5,
12–15). Thus, any increase in phospholamban phosphorylation
produced by increasing [Ca]o at low pHo would strongly suggest
a significant role of the acidosis-induced inhibition of phos-
FIG. 4. Overall results of 32P incorporation into phospholam-
ban under the same conditions described for Fig. 3. The increase
in [Ca]o failed to significantly enhance phospholamban phosphorylation
above the level achieved with isoproterenol at [Ca]o 5 1.35 mM. The
number of experiments in each treatment group is indicated in
parentheses.
FIG. 5. A, immunoblots of SR membrane vesicles isolated from rat
hearts perfused at two different isoproterenol (Iso) concentrations, 3
and 30 nM, at pHo 7.40 in the absence and presence of 1 mM okadaic acid
(OA). To compare the effects of okadaic acid with those of acidosis, SR
membranes obtained from hearts perfused with 3 and 30 nM isoproter-
enol at pHo 6.80 were run in parallel. Blots were probed as described for
Fig. 1B. B, overall results obtained after densitometric analysis of the
signal of three to six immunoblots. Results are expressed as a percent-
age as described for Fig. 2. Okadaic acid enhanced the isoproterenol-
induced increase in phosphorylation of both Ser16 or Thr17 at the two
isoproterenol concentrations tested. This finding revealed that even at
the higher isoproterenol concentration, phosphatases are not maxi-
mally inhibited and therefore can be inhibited by acidosis. As already
shown in Figs. 1B and 2, acidosis enhanced only isoproterenol-induced
Thr17 phosphorylation without affecting Ser16 phosphorylation. PSer16-
PHL and PThr17-PHL, anti-Ser16 and anti-Thr17 PHL phosphopeptides,
respectively.
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phatases in this effect. Fig. 6 shows the overall results of the
experiments performed in SR membrane vesicles from hearts
perfused with 32P and then at low and high [Ca]o at pHo 7.40
and 6.80. The increase in [Ca]o significantly increased phos-
phorylation of phospholamban only under acidotic conditions.
Fig. 7A shows immunoblots of SR membrane vesicles isolated
from hearts perfused as described for Fig. 6, except that 32P
perfusion was omitted. Immunological detection of the two
phosphorylation sites of phospholamban showed that the in-
crease in phospholamban phosphorylation observed in Fig. 6
was exclusively due to the phosphorylation of Thr17. The over-
all results of this series are shown in Fig. 7B. Table I shows the
mechanical results of this experimental series. Acidosis pro-
duced a significant decrease in 1Ṗ and t1⁄2 at [Ca]o 5 1.35 mM
that was not associated with any significant increase in phos-
pholamban phosphorylation. At [Ca]o 5 3.85 mM, acidosis pro-
duced a decrease in 1Ṗ similar to that produced at low [Ca]o
and a significant decrease in t1⁄2 that occurred in association
with the increase in Thr17 phosphorylation.
Contribution of Acidosis-induced Thr17 Phosphorylation to
the Relaxant Effect of Acidosis—As shown in Table I, the aci-
dosis-induced relaxant effect at high [Ca]o in the absence of
isoproterenol was not greater than at [Ca]o 5 1.35 mM, as
would be expected from the significant increase in Thr17 phos-
phorylation observed at high [Ca]o. Similarly, the decrease in
t1⁄2 induced by acidosis in the presence of isoproterenol was not
higher than that produced by acidosis in the absence of the
b-agonist. To further explore this point, additional experiments
were performed in which the effect of acidosis on Thr17 phos-
phorylation and t1⁄2 was studied at high [Ca]o in the presence
and absence of a 10 mM concentration of the CaMKII inhibitor
KN-62. In these experiments, acidosis produced an increase in
Thr17 phosphorylation (expressed as percent of the phosphoryl-
ation of Thr17 at 30 nM isoproterenol, run in parallel) from
24.6 6 8.3 to 82.4 6 19.8%, which returned to control levels
(28.6 6 10.9%) in the presence of 10 mM KN-62 (n 5 5). These
changes in Thr17 phosphorylation were paralleled by changes
in t1⁄2. The corresponding t1⁄2 values were 65.3 6 4.1, 55.3 6 4.4,
and 66.0 6 4.9 ms at high [Ca]o, high [Ca]o 1 acidosis, and high
[Ca]o 1 acidosis 1 KN-62, respectively. These results indicated
that the increase in Thr17 phosphorylation evoked by acidosis
was closely associated with a relaxant effect. It is possible that
at high [Ca21]i levels, as should occur at high [Ca]o and in the
presence of isoproterenol, the tension developed by the con-
tractile proteins may be close to or at the “plateau” of the
[Ca21]i-tension curve. Under these conditions, the acidosis-
induced decrease in myofilament calcium sensitivity and the
resultant relaxant effect might be minimized. This effect would
be further minimized in the presence of isoproterenol by the
decrease in myofilament calcium sensitivity produced by the
b-agonist.
DISCUSSION
Phosphorylation site-specific antibodies have proven to be
highly specific in the discrimination between the two sites of
phosphorylation of phospholamban since no cross-reactivity
with the other site of phosphorylation was observed (5). The
combination of this technique with the quantification of 32P
incorporation into phospholamban along with simultaneous
measurements of mechanical parameters constitute invaluable
tools to characterize the underlying mechanisms of phospho-
lamban phosphorylation and their regulation.
Isoproterenol-induced phospholamban phosphorylation has
been shown to be dependent upon the acid-base status of the
myocardium, with acidosis enhancing the increase in phospho-
lamban phosphorylation produced by the b-adrenergic agonist
(Ref. 16 and our results in Fig. 1A). The relevant findings of
this study were that the increase in the isoproterenol-induced
phospholamban phosphorylation produced by acidosis was ex-
clusively due to an increase in phosphorylation of Thr17 of
phospholamban (Figs. 1B and 2) and that this increase would
contribute to the enhancement of the relaxant effect of isopro-
terenol evoked by acidosis (Table I). The results also provided
evidence that an activation of CaMKII and an inhibition of
phosphatases may have both played a significant role in the
observed increase in Thr17 phosphorylation produced by acido-
sis in the presence of isoproterenol.
Phosphorylation of phospholamban depends on a basic mech-
anism that is common to any phosphorylation process, i.e. the
relative activities of kinases and phosphatases that phospho-
rylate and dephosphorylate the protein, respectively. b-Adre-
noreceptor stimulation increases phospholamban phosphoryl-
ation by increasing the phosphorylation of both Ser16 and Thr17
(4, 5). Different types of evidence further indicate that this dual
phosphorylation occurs because isoproterenol not only in-
creases PKA activity, but as a consequence of PKA activation,
also produces a simultaneous activation of CaMKII (by increas-
ing [Ca21]i) and inhibition of PP1, the major phosphatase that
dephosphorylates phospholamban (6–11). In this context and
in the search for the mechanisms underlying the enhancement
of the isoproterenol-induced phospholamban phosphorylation
produced by acidosis, two possibilities should be necessarily
explored: 1) acidosis produces a further increase in CaMKII
activity, and/or 2) acidosis evokes a further inhibition of PP1.
Both possibilities have some experimental support (16–18).
First, it has been shown in several species that hypercapnic
acidosis increases [Ca21]i more in the presence than in the
absence of isoproterenol (17, 18). This increase in [Ca21]i may
add to the increase in [Ca21]i produced by isoproterenol to
further activate CaMKII. Second, it has also been shown that
acidosis inhibits PP1. A decrease in pHo from 7.40 to 6.80
produced by increasing the CO2 of the gas mixture from 5 to
FIG. 6. Overall results of 32P incorporation into PHL in SR
membrane vesicles isolated from rat hearts perfused with 32P
and then with Ringer’s solution containing 1.35 mM [Ca]o at pHo
7.40 or 6.80 or 3.85 mM [Ca]o at pHo 7.40 or 6.80. Acidosis failed to
phosphorylate PHL at [Ca]o 5 1.35 mM, but increased PHL phospho-
rylation at high [Ca]o.
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20% (external bicarbonate of 18.5 mM) has been reported to
produce a decrease in pHi from 7.14 to ;6.70 in isolated cat and
guinea pig myocytes (23). Similar results were obtained by us
in experiments performed in rat isolated myocytes under the
same conditions described in the present experiments. In these
experiments, the pHi decreased from 7.18 6 0.06 to 6.73 6
0.04.2 In this pHi range, we have previously shown in in vitro
experiments that PP1 was inhibited by acidosis by ;30% (16).
Previous results have shown that the increase in [Ca]o pro-
duced an increase in Thr17 phosphorylation only when the
phosphatases were inhibited as in the presence of okadaic acid
(5). In the present experiments, acidosis produced effects sim-
ilar to those observed with okadaic acid: the activation of
CaMKII by increasing [Ca]o in the absence of isoproterenol
evoked an increase in Thr17 phosphorylation only under aci-
dotic conditions (Fig. 7). This finding indicates that the acido-
sis-induced inhibition of phosphatases played a significant role
in the increase in Thr17 phosphorylation observed. Moreover,
the increase in Thr17 phosphorylation was closely paralleled by
a relaxant effect. The fact that, at [Ca]o 5 1.35 mM, acidosis did
not produce any significant change in either Ser16 or Thr17
means that for the level of phosphatase inhibition produced by
acidosis, the activity of kinases was too low to increase the
hosphorylation of the corresponding residues.
The acidosis enhancement of isoproterenol-induced Thr17
phosphorylation could be mimicked by either increasing [Ca]o
(Fig. 3) or adding okadaic acid (Fig. 5). These findings indicated
that the CaMKII cascade can be activated above the level
achieved by stimulation with isoproterenol and that even at the
higher isoproterenol concentration used, phosphatases are not
maximally inhibited by cAMP and therefore can be further
inhibited by acidosis. However, neither the increase in [Ca]o
nor the presence of okadaic acid mimicked the lack of effect of
acidosis on Ser16. Whereas okadaic acid significantly enhanced
the isoproterenol-induced phosphorylation of Ser16, the in-
crease in [Ca]o significantly decreased it. The results obtained
on phosphorylation of Ser16 under the different experimental
situations are therefore consistent with the hypothesis that
acidosis was acting by two different mechanisms, i.e. the in-
crease in [Ca21]i and the inhibition of phosphatases, both of
which contribute to the increase in Thr17 phosphorylation, but
have opposite effects on Ser16 phosphorylation.
The decrease in Ser16 phosphorylation when [Ca]o was in-
creased in the presence of isoproterenol (Fig. 3) was an unex-
pected finding that deserves some additional comments. 1) The
result is in line with the fact that the increase in [Ca]o in the
presence of the b-agonist failed to significantly increase total
2 L. Vittone, C. Mundiña-Weilenmann, M. Said, and A. Mattiazzi,
unpublished results.
FIG. 7. A, immunoblots of SR membrane vesicles isolated from rat hearts perfused as described for Fig. 6. Site-specific phosphorylation produced
by 30 nM isoproterenol (Iso) is shown for comparison. B, overall results obtained after densitometric analysis of the signal of three immunoblots.
At [Ca]o 5 1.35 mM, acidosis failed to significantly increase either Ser
16 or Thr17 phosphorylation. At [Ca]o 5 3.85 mM, acidosis did not affect Ser
16
phosphorylation, but produced an evident enhancement of Thr17 phosphorylation, which would account for the increase in total PHL phospho-
rylation observed in Fig. 6. PSer16-PHL and PThr17-PHL, anti-Ser16 and anti-Thr17 PHL phosphopeptides, respectively; PHLH and PHLL,
pentameric and monomeric forms of PHL, respectively.
Acidosis and Phosphorylation of Phospholamban9810
phospholamban phosphorylation (Fig. 4) and myocardial relax-
ation (Table I) above the levels attained by b-adrenoreceptor
stimulation. 2) As discussed above, the result is also consistent
with the idea that both the activation of CaMKII and the
inhibition of phosphatases have contributed to the enhance-
ment of the isoproterenol-induced Thr17 phosphorylation pro-
duced by acidosis. The cause for this decrease in Ser16 phos-
phorylation is not apparent to us. The inhibition of type V
adenylyl cyclase, the major adenylyl cyclase isoform present in
adult ventricle (24), by submicromolar concentrations of cal-
cium has been previously described (25). However, this possi-
bility is not supported by previous experiments in our labora-
tory showing that the increase in [Ca]o did not affect
intracellular cAMP levels (14). Another possible clue to explain
the above findings can be found in the mechanisms regulating
PP1 activity. SR-associated PP1 could be inhibited by direct
PKA-dependent phosphorylation of the PP1 regulatory subunit
and PKA-dependent phosphorylation of inhibitor-1, which in
the phosphorylated state is a potent inhibitor of the catalytic
subunit of PP1 (8). In turn, the PP1 regulatory subunit and
inhibitor-1 are dephosphorylated by two other phosphatases,
PP2A and PP2B (8). Since PP2B is activated by calcium and
calmodulin, the increase in [Ca21]i is a potential mechanism by
which PP1 can be activated (8). As a consequence, the inhibi-
tory effect of PKA on PP1 would be attenuated. This phospha-
tase regulatory cascade might explain the decrease in the phos-
phorylation of Ser16 when [Ca21]i was increased.
This decrease may not occur in acidosis if it is overrided by
acidosis-induced phosphatase inhibition. The decrease in iso-
proterenol-induced Ser16 phosphorylation by increasing [Ca]o
(Fig. 3) may therefore be the expression of a mechanism by which
the increase in [Ca21]i, acting through a protein phosphatase
cascade, attenuates the signals that act via cAMP (8, 26).
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